WO2004017916A3 - Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition - Google Patents

Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition Download PDF

Info

Publication number
WO2004017916A3
WO2004017916A3 PCT/US2003/026427 US0326427W WO2004017916A3 WO 2004017916 A3 WO2004017916 A3 WO 2004017916A3 US 0326427 W US0326427 W US 0326427W WO 2004017916 A3 WO2004017916 A3 WO 2004017916A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
transfer factor
element
therapeutic methods
cardiovascular therapy
Prior art date
Application number
PCT/US2003/026427
Other languages
French (fr)
Other versions
WO2004017916A2 (en
Inventor
William J Hennen
Original Assignee
4Life Res Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US40535802P priority Critical
Priority to US60/405,358 priority
Application filed by 4Life Res Lc filed Critical 4Life Res Lc
Publication of WO2004017916A2 publication Critical patent/WO2004017916A2/en
Publication of WO2004017916A3 publication Critical patent/WO2004017916A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A composition for use in cardiovascular therapy includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels.
PCT/US2003/026427 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition WO2004017916A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US40535802P true 2002-08-22 2002-08-22
US60/405,358 2002-08-22

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003265620A AU2003265620A1 (en) 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition

Publications (2)

Publication Number Publication Date
WO2004017916A2 WO2004017916A2 (en) 2004-03-04
WO2004017916A3 true WO2004017916A3 (en) 2004-10-14

Family

ID=31946861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026427 WO2004017916A2 (en) 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition

Country Status (3)

Country Link
US (2) US7815943B2 (en)
AU (1) AU2003265620A1 (en)
WO (1) WO2004017916A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
EP1608379A1 (en) * 2003-03-27 2005-12-28 Medicure Inc. Compositions for treating angina
US6866868B1 (en) * 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US9028882B2 (en) 2005-05-02 2015-05-12 4Life Patents, Llc Nutraceutical gels
AU2006242106B2 (en) * 2005-05-02 2013-01-17 4Life Patents, Llc Transfer factor preparations and associated methods
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
NZ709245A (en) 2010-11-23 2016-11-25 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
US8815310B2 (en) * 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
US20120177631A1 (en) * 2011-01-10 2012-07-12 Morteza Naghavi Composition for Health Promoting Compounds
US10004757B1 (en) 2017-09-22 2018-06-26 Nutri Vida, LLC Oral supplement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
ES2052496T3 (en) * 1985-11-25 1994-07-16 Ghen Corp Specific antibody-containing substance derived from eggs and method for its production and use.
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
DE69127694T2 (en) * 1990-07-02 1998-04-02 Nat Jewish Ct Immun & Respirat Production and use of transfer-factor
US6203818B1 (en) * 1997-03-20 2001-03-20 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
US6022901A (en) * 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
CA2357685A1 (en) * 2000-09-18 2002-03-18 Chisolm Biological Laboratory, Llc Transfer factor composition and process for producing same
US6468534B1 (en) * 2000-09-21 2002-10-22 4Life Research, Lc Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes

Also Published As

Publication number Publication date
US9849157B2 (en) 2017-12-26
AU2003265620A8 (en) 2004-03-11
US20040126432A1 (en) 2004-07-01
US20110033414A1 (en) 2011-02-10
WO2004017916A2 (en) 2004-03-04
AU2003265620A1 (en) 2004-03-11
US7815943B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
Jayabalan et al. A review on kombucha tea—microbiology, composition, fermentation, beneficial effects, toxicity, and tea fungus
TW371628B (en) Composition for treating condyloma acuminata
EP0903143A3 (en) Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels
SG175465A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005087116A3 (en) Method and apparatus for aligning a knee for surgery or the like
MEP30308A (en) HUMAN ANTI-IFN-gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-gamma PATHWAY INHIBITORS
MD970199A (en) Induction of a cytotoxic T-lymphocytic answer The invention relates to the medicine, particularly to the immunology and can be used for treatment of bacterial and parasitic infections, tumors and other diseases. The summary of the invention consists in the induction of a cytotoxic T-lymphocytic answer to human and animals by means of a composition consisting of an antigene and an antigenic formulati
NO20075834L (en) Dosage forms for chelating agent
WO2009118662A3 (en) Methods and compositions for treating bone loss
EP1575480A4 (en) Compositions and methods for the treatment of immune related diseases
EP1578367A4 (en) Compositions and methods for the treatment of immune related diseases
DK0653911T3 (en) Methods for the inactivation of bacteria in the blood products with 8-methoxypsoralen
EA200400291A1 (en) Food therapy for patients with immunity disorder
EP2364716A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
EA200900681A1 (en) Composition for the treatment of respiratory synctial viruses
RU95108231A (en) Glp-1-molecular complex, pharmaceutical composition and method of complex preparing
WO2000023955A8 (en) Virus-like particles for the induction of autoantibodies
WO2005001079A3 (en) Soft tissue repair and regeneration using postpartum-derived cells
EP2269616A3 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
WO2002047612A3 (en) Dietary supplement compositions
WO2008100292A8 (en) Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
NO336528B1 (en) Antistoffinhibitorer of GDF-8 and use thereof

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP